ONCOLOGY · ADVANCED SOLID TUMORS
ONM-501 advanced solid tumor and lymphoma study
Information about a Phase 1 clinical study of intratumoral ONM-501 alone and with cemiplimab.
Study overview
This Phase 1 dose-escalation and expansion study is evaluating ONM-501 in people with advanced solid tumors and lymphomas. The protocol includes ONM-501 administered directly into a tumor, both by itself and in combination with cemiplimab. Intratumoral administration means the study treatment is delivered into a selected tumor site. Whether a tumor is suitable for this approach is determined through protocol-specific review.
What early-phase research examines
Phase 1 research commonly evaluates safety, tolerability, dose selection, and how an investigational treatment behaves in the body. Study procedures may include physical examinations, laboratory testing, imaging, tumor assessments, and monitoring for side effects. The exact schedule and required procedures depend on the assigned study group. ONM-501 is investigational, and its potential benefits and risks are not fully established. Cemiplimab also has specific risks that the research team reviews during informed consent.
Asking about participation
Eligibility may depend on cancer type, disease history, previous treatment, general health, measurable or injectable tumor sites, and other protocol requirements. Study availability can change as dose levels or expansion groups open, pause, or close. Screening does not guarantee enrollment, and contacting the institute does not obligate you to participate.
Participation is voluntary. Before deciding, you may review the study with your physician, family, or another trusted adviser. The study team will explain required visits, foreseeable risks, alternatives, and participant rights.
For current information, call (323) 660-6200 or email trials@caresinst.org. Please do not email medical records, insurance details, or sensitive health information. This page is educational and does not replace medical advice.